Breast cancer therapy-associated cardiovascular disease (original) (raw)

• Lee, M. S., Finch, W. & Mahmud, E. Cardiovascular complications of radiotherapy. Am. J. Cardiol. 112, 1688–1696 (2013).
  Article PubMed Google Scholar
• Darby S. C. et al. Radiation-related heart disease: current knowledge and future prospects. Int. J. Radiat. Oncol. Biol. Phys. 76, 656–665 (2010).
  Article PubMed PubMed Central Google Scholar
• Cuzick, J. et al. Overview of randomized trials of postoperative adjuvant radiation therapy in breast cancer. Cancer Treat. Rep. 71, 15–29 (1987).
  CAS PubMed Google Scholar
• Cuzick, J. et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J. Clin. Oncol. 12, 447–453 (1994).
  Article CAS PubMed Google Scholar
• Host, H., Brennhovd, I. O. & Loeb, M. Postoperative radiotherapy in breast cancer—long-term results from the Oslo study. Int. J. Radiat. Oncol. Biol. Phys. 12, 727–732 (1986).
  Article CAS PubMed Google Scholar
• Haybittle, J. L., Brinkley, D., Houghton, J., A'Hern, R. P. & Baum, M. Postoperative radiotherapy and late mortality: evidence from the Cancer Research Campaign trial for early breast cancer. BMJ 298, 1611–1614 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Rutqvist, L. E., Lax, I., Fornander, T., A'Hern, R. P. & Baum, M. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 22, 887–896 (1992).
  Article CAS PubMed Google Scholar
• Rutqvist, L. E. & Johansson, H. Mortality by laterality of the primary tumor among 55,000 breast cancer patients from the Swedish Cancer Registry. Br. J. Cancer 61, 866–868 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Hojris, I., Overgaard, M., Christensen, J. J. & Overgaard, J. Morbidity and mortality of ischemic heart disease in high-risk breast cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomized trials. Lancet 354, 1425–1430 (1999).
  Article CAS PubMed Google Scholar
• Harris, E. E. et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast conservation treatment. J. Clin. Oncol. 24, 4100–4106 (2006).
  Article PubMed Google Scholar
• Paszat, L. F. et al. A population-based case-cohort study of the risk of myocardial infarction following radiation therapy for breast cancer. Radiother. Oncol. 82, 294–300 (2007).
  Article PubMed Google Scholar
• Correa, C. R. et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J. Clin. Oncol. 25, 3031–3037 (2007).
  Article PubMed Google Scholar
• Hooning, M. J. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J. Natl Cancer Inst. 99, 365–375 (2007).
  Article PubMed Google Scholar
• Borger, J. H. et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int. J. Radiat. Oncol. Biol. Phys. 69, 1131–1138 (2007).
  Article PubMed Google Scholar
• Cvancarova, M. et al. Risk of death from cardiovascular disease in long-term breast cancer survivors: a comparison with women from the general population [abstract]. J. Clin. Oncol. 32, S5 a1534 (2014).
  Article Google Scholar
• Clarke, M. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366, 2087–2106 (2005).
  Article CAS PubMed Google Scholar
• Janjan, N. A. et al. Dose to the cardiac vascular and conduction systems in primary breast irradiation. Med. Dosim. 14, 81–87 (1989).
  Article CAS PubMed Google Scholar
• Nieder, C., Schill, S., Kneschaurek, P. & Molls, M. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat. Oncol. 2, 20 (2007).
  Article PubMed PubMed Central Google Scholar
• Taylor, C. W., Nisbet, A., McGale, P. & Darby, S. C. Cardiac exposures in breast cancer radiotherapy: 1950's–1990's. Int. J. Radiat. Oncol. Biol. Phys. 69, 1484–1495 (2007).
  Article PubMed Google Scholar
• Taylor, C. W. et al. Cardiac dose from contemporary tangential breast cancer radiotherapy in the year 2006. Int. J. Radiat. Oncol. Biol. Phys. 72, 501–507 (2008).
  Article PubMed Google Scholar
• Nilsson, G. et al. Distribution of coronary artery stenosis after radiation for breast cancer. J. Clin. Oncol. 30, 380–386 (2012).
  Article PubMed Google Scholar
• Darby, S. C. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987–998 (2013).
  Article CAS PubMed Google Scholar
• Marks, L. B. et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int. J. Radiat. Oncol. Biol. Phys. 63, 214–223 (2005).
  Article PubMed Google Scholar
• Bell, L. . J. Cox, J., Eade, T. & Rinks, M. & Kneebone, A. The impact of rectal and bladder variability on target coverage during post-prostatectomy intensity modulated radiotherapy. Radiother. Oncol. 110, 245–250 (2014).
  Article PubMed Google Scholar
• de Crevoisier, R. et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int. J. Radiat. Biol. Oncol. Phys. 62, 965–973 (2005).
  Article Google Scholar
• Heemsbergen, W. D. et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68Gy versus 78 Gy. Int. J. Radiat. Oncol. Biol. Phys. 67, 1418–1424 (2007).
  Article CAS PubMed Google Scholar
• Michalski, J. M. et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int. J. Radiat. Oncol. Biol. Phys. 46, 391–402 (2000).
  Article CAS PubMed Google Scholar
• Gyenes, G., Fornander, T., Carlens, P., Glas, U. & Rutqvist, L. E. Myocardial damage in breast cancer patients treated with adjuvant radiotherapy: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 36, 899–905 (1996).
  Article CAS PubMed Google Scholar
• Prosnitz, R. G. et al. Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 110, 1840–1850 (2007).
  Article PubMed Google Scholar
• Ishii, J. et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am. J. Cardiol. 89, 691–695 (2002).
  Article CAS PubMed Google Scholar
• Perna, E. R. et al. Ongoing myocardial injury in stable severe heart failure: value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110, 2376–2382 (2004).
  Article PubMed Google Scholar
• Nellessen, U. et al. Serial analysis of troponin I levels in patients with ischemic and nonischemic dilated cardiomyopathy. Clin. Cardiol. 29, 219–224 (2006).
  Article PubMed PubMed Central Google Scholar
• Nellessen, U., Zingel, M., Hecker, H., Bahnsen, J. & Borschke, D. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? Chemotherapy 56, 147–152 (2010).
  Article CAS PubMed Google Scholar
• Hughes-Davies, L., Sacks, D., Rescigno, J., Howard, S. & Harris, J. Serum cardiac troponin T levels during treatment of early-stage breast cancer. J. Clin. Oncol. 13, 2582–2584 (1995).
  Article CAS PubMed Google Scholar
• Kozak, K. R. et al. Cardiac blood biomarkers in patients receiving thoracic (chemo)radiation. Lung Cancer 62, 351–355 (2008).
  Article PubMed Google Scholar
• Cardinale, D., Salvatici, M. & Sandri, M. T. Role of biomarkers in cardioncology. Clin. Chem. Lab. Med. 49, 1937–1948 (2011).
  Article CAS PubMed Google Scholar
• Christenson, E. S., James, T., Agrawal, V. & Park, B. H. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin. Biochem. 48, 223–235 (2015).
  Article CAS PubMed Google Scholar
• Hancock, S. L., Tucker, M. A. & Hoppe, R. T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. J. Am. Med. Assoc. 270, 1949–1955 (1993).
  Article CAS Google Scholar
• Bradley, J. D. et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16, 187–199 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Hardy, D., Liu, C. C., Cormier, J. N., Xia, R. & Du, X. L. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann. Oncol. 21, 1825–1833 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Wilson, P. W. et al. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837–1847 (1998).
  Article CAS PubMed Google Scholar
• Grundy, S. M., Pasternak, R., Greenland, P., Smith, S. Jr & Fuster, V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J. Am. Coll. Cardiol. 34, 1348–1359 (1999).
  Article CAS PubMed Google Scholar
• Ridker, P. M., Buring, J. E., Rifai, N. & Cook, N. R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds score. J. Am. Med. Assoc. 297, 611–619 (2007).
  Article CAS Google Scholar
• Paszat, L. F., Mackillop, W. J., Groome, P. A., Schulze, K. & Holowaty, E. Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: A population-based study in Ontario, Canada. Int. J. Radiat. Oncol. Biol. Phys. 43, 755–761 (1999).
  Article CAS PubMed Google Scholar
• Hooning, M. J. et al. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int. J. Radiat. Oncol. Biol. Phys. 64, 1081–1091 (2007).
  Article Google Scholar
• Brenner, D. J., Shuryak, I., Jozsef, G., Dewyngaert, K. J. & Formenti, S. C. Risk and risk reduction of major coronary events associated with contemporary breast radiotherapy. JAMA Intern. Med. 174, 158–160 (2014).
  Article PubMed Google Scholar
• Suter, T. M. & Ewer, M. S. Cancer drugs and the heart: importance and management. Eur. Heart J. 34, 1102–1111 (2013).
  Article CAS PubMed Google Scholar
• Lenihan D. J. & Cardinale, D. Late cardiac effects of cancer treatment. J. Clin. Oncol. 30, 3657–3664 (2012).
  Article PubMed Google Scholar
• Jessup, M. et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 53, 1343–1382 (2009).
  Article Google Scholar
• Hahn, V. S., Lenihan, D. J. & Ky, B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J. Am. Heart Assoc. 3, e000665 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639–1642 (2012).
  Article CAS PubMed Google Scholar
• Yeh, E. T. & Bickford, C. L. Cardiovascular complications of cancer therapy. Incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53, 2231–2247 (2009).
  Article CAS PubMed Google Scholar
• Jones, L. W., Haykowsky, M. J., Swartz, J. J., Douglas, P. S. & Mackey, J. R. Early breast cancer therapy and cardiovascular injury. J. Am. Coll. Cardiol. 50, 1435–1441 (2007).
  Article PubMed Google Scholar
• Von Hoff, D. D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710–717 (1979).
  Article CAS PubMed Google Scholar
• Bowles, E. J. et al. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J. Natl Cancer Inst. 104, 1293–1305, (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Carver, J. R., Szalda, D. & Ky, B. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin. Oncol. 40, 229–238 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459–465 (2002).
  Article CAS PubMed Google Scholar
• Lee, K. F. et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development Nature 378, 394–398 (1995).
  Article CAS PubMed Google Scholar
• Harbeck, N., Ewer, M. S., De Laurentiis, M., Suter, T. M. & Ewer, S. M. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann. Oncol. 22, 1250–1258 (2011).
  Article CAS PubMed Google Scholar
• Ewer, S. M. & Ewer, M. S. Carditoxicity profile of trastuzumab. Drug Saf. 31, 459–467 (2008).
  Article CAS PubMed Google Scholar
• Halyard, M. Y. et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J. Clin. Oncol. 27, 2638–2644 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Shapiro, C. L. et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J. Clin. Oncol. 16, 3493–3501 (1998).
  Article CAS PubMed Google Scholar
• Valagussa, P. et al. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer. Ann. Oncol. 5, 209–216 (1994).
  Article CAS PubMed Google Scholar
• Cardinale, D., Bacchiani, G., Beggiato, M., Colombo, A. & Cipolla. C. M. Strategies to prevent and treat cardiovascular risk in cancer patients. Semin. Oncol. 40, 186–198 (2013).
  Article CAS PubMed Google Scholar
• Thavendiranathan, P. et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63, 2751–2768 (2014).
  Article PubMed Google Scholar
• Tamene, A. M., Masri, C. & Konety, S. H. Cardiovascular MR imaging in cardio-oncology. Magn. Reson. Imaging Clin. N. Am. 23, 105–116 (2015).
  Article PubMed Google Scholar
• Cardinale, D. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 55, 213–220 (2010).
  Article CAS PubMed Google Scholar
• Curigliano, G. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 23, S55–S66 (2012).
  Article Google Scholar
• Telli, M. L., Hunt, S. A., Carlson, R. W. & Guardino, A. E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25, 3525–3533 (2007).
  Article CAS PubMed Google Scholar
• Tocchetti . et al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur. J. Heart Fail. 14, 130–137 (2012).
  Article CAS PubMed Google Scholar
• Mackey, J. R. et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr. Oncol. 15, 24–35 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sengupta, P. P., Northfelt, D. W., Gentile, F., Zamorano, J. L. & Khandheria, B. K. Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin. Proc. 83, 197–203 (2008).
  Article CAS PubMed Google Scholar
• Jones, A. L. et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br. J. Cancer 100, 684–692 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, M. et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14, 1–11 (2009).
  Article CAS PubMed Google Scholar
• Fyles, A. W. et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N. Engl. J. Med. 351, 963–970 (2004).
  Article CAS PubMed Google Scholar
• Hughes, K. S. et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J. Clin. Oncol. 31, 2382–2387 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Fisher, B. et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin. Oncol. 28, 400–418 (2001).
  Article CAS PubMed Google Scholar
• Houghton, J. et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362, 95–102 (2003).
  Article PubMed Google Scholar
• Bijker, N. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J. Clin. Oncol. 24, 3381–3387 (2006).
  Article PubMed Google Scholar
• Holmberg, L. et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J. Clin. Oncol. 26, 1247–1252 (2008).
  Article PubMed Google Scholar
• Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817–2826 (2004).
  Article CAS PubMed Google Scholar
• Dragun, A. E. et al. Increasing mastectomy rates among all age groups for early stage breast cancer: a 10-year study of surgical choice. Breast J. 18, 318–325 (2012).
  Article PubMed Google Scholar
• Fisher, C. S. et al. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann. Surg. Oncol. 19, 3246–3250 (2012).
  Article PubMed Google Scholar
• Mahmood, U. et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann. Surg. Oncol. 20, 1436–1443 (2013).
  Article PubMed Google Scholar
• Wang, X. et al. Cardiac motion during deep-inspiration breath-hold: implications for breast cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 82, 708–714 (2012).
  Article PubMed Google Scholar
• Bruzzaniti, V. et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J. Exp. Clin. Cancer Res. 32, 88 (2013).
  Article PubMed PubMed Central Google Scholar
• Tang, X. et al. Clinical experience with 3-dimensional surface matching-based deep inspiration breath hold for left-sided breast cancer radiation therapy. Pract. Radiat. Oncol. 4, e151–e158 (2014).
  Article PubMed Google Scholar
• Zagar, T. M. et al. Prospective assessment of deep inspiration breath hold to prevent radiation associated cardiac perfusion defects in patients with left-sided breast cancer [abstract 2027]. Presented at the ASTRO Annual meeting, San Antonio, TX (2015).
• Zellars, R. et al. SPECT analysis of cardiac perfusion changes after whole-breast/chest wall radiation therapy with or without active breathing coordinator: results of a randomized phase 3 trial. Int. J. Radiat. Oncol. Biol. Phys. 15, 778–785 (2014).
  Article Google Scholar
• Formenti, S. C., DeWyngaert, J. K., Jozsef, G. & Goldberg, J. D. Prone vs supine positioning for breast cancer radiotherapy. JAMA 308, 861–863 (2012).
  Article CAS PubMed Google Scholar
• Chino, J. P. & Marks, L. B. Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment. Int. J. Radiat. Oncol. Biol. Phys. 70, 916–920 (2008).
  Article PubMed Google Scholar
• Würschmidt, F., Stoltenberg, S., Kretschmer, M. & Petersen, C. Incidental dose to coronary arteries is higher in prone than in supine whole breast irradiation. A dosimetric comparison in adjuvant radiotherapy of early stage breast cancer. Strahlenther Onkol. 190, 563–568 (2014).
  Article PubMed Google Scholar
• Mulliez, T. et al. Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. Radiother. Oncol. 114, 79–84 (2015).
  Article PubMed Google Scholar
• Kalay, N. et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 48, 2258–2262 (2006).
  Article CAS PubMed Google Scholar
• Kaya, M. G. et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int. J. Cardiol. 167, 2306–2310 (2013).
  Article PubMed Google Scholar
• Seicean, S. et al. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ. Heart Fail. 6, 420–426 (2013).
  Article CAS PubMed Google Scholar
• Nakamae, H. et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 104, 2492–2498 (2005).
  Article CAS PubMed Google Scholar
• Cadeddu, C. et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am. Heart J. 160, e1–e7 (2010).
  Article CAS Google Scholar
• Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474–2481 (2006).
  Article CAS PubMed Google Scholar
• Bosch, X. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61, 2355–2362 (2013).
  Article CAS PubMed Google Scholar
• Kalam, K. & Marwick, T. H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur. J. Cancer 49, 2900–2909 (2013).
  Article CAS PubMed Google Scholar
• Seicean, S., Seicean, A., Plana, J. C., Budd, G. T. & Marwick, T. H. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J. Am. Coll. Cardiol. 60, 2384–2390 (2012).
  Article CAS PubMed Google Scholar
• Acar, Z. et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 58, 988–989 (2011).
  Article PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2015).
• Truong, J., Yan, A. T., Cramarossa, G. & Chan, K. K. Chemotherapy-induced cardiotoxicity: detection, prevention and management. Can. J. Cardiol. 30, 869–878 (2014).
  Article PubMed Google Scholar